Yiman Shang

442 total citations
15 papers, 185 citations indexed

About

Yiman Shang is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yiman Shang has authored 15 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yiman Shang's work include Cancer Immunotherapy and Biomarkers (9 papers), Immune Cell Function and Interaction (5 papers) and CAR-T cell therapy research (4 papers). Yiman Shang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immune Cell Function and Interaction (5 papers) and CAR-T cell therapy research (4 papers). Yiman Shang collaborates with scholars based in China and United States. Yiman Shang's co-authors include Quanli Gao, Yong Zhang, Zibing Wang, Yuqing Liu, Yonghao Yang, Lingdi Zhao, Yongping Song, Lu Han, Xiaomin Fu and Hongwei Lin and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Yiman Shang

15 papers receiving 183 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yiman Shang China 8 157 103 36 32 15 15 185
Lucile Vanhersecke France 5 105 0.7× 63 0.6× 38 1.1× 18 0.6× 9 0.6× 17 133
Miya Haruna Japan 8 104 0.7× 100 1.0× 27 0.8× 23 0.7× 19 1.3× 10 160
Keisuke Onoi Japan 3 114 0.7× 42 0.4× 72 2.0× 23 0.7× 11 0.7× 5 157
Akiko Morimoto-Okazawa Japan 9 195 1.2× 173 1.7× 53 1.5× 33 1.0× 56 3.7× 9 280
Masaki Sunagawa Japan 6 96 0.6× 38 0.4× 39 1.1× 34 1.1× 45 3.0× 34 144
André Vanoli France 4 155 1.0× 121 1.2× 27 0.8× 17 0.5× 6 0.4× 6 203
Marc‐Olivier Sauvain Switzerland 5 82 0.5× 82 0.8× 26 0.7× 30 0.9× 31 2.1× 11 161
Marie Naigeon France 9 163 1.0× 78 0.8× 86 2.4× 34 1.1× 10 0.7× 21 212
Shaun Tiwari United States 3 112 0.7× 100 1.0× 20 0.6× 33 1.0× 6 0.4× 3 178
Soizick Mesnage France 6 167 1.1× 102 1.0× 41 1.1× 49 1.5× 36 2.4× 9 260

Countries citing papers authored by Yiman Shang

Since Specialization
Citations

This map shows the geographic impact of Yiman Shang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiman Shang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiman Shang more than expected).

Fields of papers citing papers by Yiman Shang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiman Shang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiman Shang. The network helps show where Yiman Shang may publish in the future.

Co-authorship network of co-authors of Yiman Shang

This figure shows the co-authorship network connecting the top 25 collaborators of Yiman Shang. A scholar is included among the top collaborators of Yiman Shang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiman Shang. Yiman Shang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Zhang, Yong, Chaoji Zhang, Peng Qin, et al.. (2025). Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy. Scientific Reports. 15(1). 28995–28995. 1 indexed citations
2.
Xu, Benling, Tingjie Wang, Peng Qin, et al.. (2025). The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis. Scientific Reports. 15(1). 17450–17450. 1 indexed citations
3.
4.
Shang, Yiman, Yong Zhang, Xiaomin Fu, et al.. (2022). Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer. Frontiers in Oncology. 12. 852885–852885. 5 indexed citations
5.
Zhao, Lingdi, Wenqun Xing, Yonghao Yang, et al.. (2021). The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.. Journal of Clinical Oncology. 39(15_suppl). 4051–4051. 13 indexed citations
6.
Zhang, Yong, Fang Zhang, Lingdi Zhao, et al.. (2021). Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. BMC Gastroenterology. 21(1). 399–399. 3 indexed citations
7.
Zhao, Lingdi, Yonghao Yang, Wei Li, et al.. (2019). Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. Journal of Oncology. 2019. 1–8. 9 indexed citations
8.
Fu, Xiaomin, Yong Zhang, Jing Yang, et al.. (2018). Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer. OncoTargets and Therapy. Volume 11. 6091–6100. 13 indexed citations
9.
Zhang, Yong, et al.. (2018). Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanoma. International Immunopharmacology. 56. 143–147. 17 indexed citations
10.
Zhao, Lingdi, Lu Han, Yong Zhang, et al.. (2018). Combination of Pd-1 Blockade and Retronectin ® -Activated Cytokine-Induced Killer in Preheavily Treated Non-Small-Cell Lung Cancer: A Retrospective Study. Immunotherapy. 10(15). 1315–1323. 6 indexed citations
11.
Zhao, Lingdi, Wei Li, Zibing Wang, et al.. (2018). Survival Benefit from RectroNectin-Activated Cytokine-Induced Killer Cells Combined with Chemotherapy in Advanced EGFR Wild-Type Lung Adenocarcinoma. Immunotherapy. 10(6). 501–510. 5 indexed citations
12.
13.
Wang, Zibing, Yuqing Liu, Yiman Shang, et al.. (2016). Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. Journal of Hematology & Oncology. 9(1). 6–6. 31 indexed citations
14.
Han, Lu, Yiman Shang, Yongping Song, & Quanli Gao. (2016). Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells. Journal of Immunology Research. 2016. 1–11. 15 indexed citations
15.
Wang, Zibing, Yuqing Liu, Yong Zhang, Yiman Shang, & Quanli Gao. (2015). MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget. 7(4). 4760–4769. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucile Vanhersecke Breakdown of academic impact, for papers by Miya Haruna Breakdown of academic impact, for papers by Keisuke Onoi Breakdown of academic impact, for papers by Akiko Morimoto-Okazawa Breakdown of academic impact, for papers by Masaki Sunagawa Breakdown of academic impact, for papers by André Vanoli Breakdown of academic impact, for papers by Marc‐Olivier Sauvain Breakdown of academic impact, for papers by Marie Naigeon Breakdown of academic impact, for papers by Shaun Tiwari Breakdown of academic impact, for papers by Soizick Mesnage
Rankless by CCL
2026